Neisseria meningitidis compositions and methods thereof
Annaliesa Sybil Anderson, Upper Saddle River, NJ (US); Rasappa Gounder Arumugham, Lansdale, PA (US); John Erwin Farley, Chapel Hill, NC (US); Leah Diane Fletcher, Geneseo, NY (US); Shannon Lea Harris, Nanuet, NY (US); Kathrin Ute Jansen, New York, NY (US); Thomas Richard Jones, New City, NY (US); Lakshmi Khandke, Nanuet, NY (US); Bounthon Loun, North Reading, MA (US); John Lance Perez, Doylestown, PA (US); and Gary Warren Zlotnick, San Antonio, TX (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Dec. 18, 2020, as Appl. No. 17/126,712.
Application 15/728,610 is a division of application No. 14/470,922, filed on Aug. 27, 2014, granted, now 9,822,150, issued on Nov. 21, 2017.
Application 17/126,712 is a continuation of application No. 15/728,610, filed on Oct. 10, 2017, granted, now 10,899,802.
Claims priority of provisional application 61/989,432, filed on May 6, 2014.
Claims priority of provisional application 61/926,717, filed on Jan. 13, 2014.
Claims priority of provisional application 61/875,068, filed on Sep. 8, 2013.
Prior Publication US 2021/0101943 A1, Apr. 8, 2021
1. A method of inducing a bactericidal immune response in a human against a Neisseria meningitidis serogroup B subfamily A strain and against a Neisseria meningitidis serogroup B subfamily B strain, comprising administering to the human an effective amount of a composition comprising polypeptide antigens from N. meningitidis serogroup B, wherein said antigens consist of: a) a first lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1, and b) a second lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2; wherein the method further comprises administering to the human an immunogenic composition against human papillomavirus (HPV), wherein the HPV antigens in said immunogenic composition consist of recombinant L1 protein antigens of HPV types 6, 11, 16, and 18.